The USA-based company's development programs include infectious diseases resulting from outbreaks and pandemics, as well as immunological, gastroenterological, and respiratory diseases that have significant mortality and health impacts on immune compromised patients.

SAB has applied advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine. Its DiversitAb platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, fully-human polyclonal immunotherapies without the need for human donors.

As of Q2 2023, SAB has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies.